Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Omicron Pharmaceuticals100 enrolled

Overview

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Atherosclerosis

Interventions

AterononDRUG

Ateronon daily for 3 months

Eligibility

Sex: ALLMin age: 35 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Men and Women with demonstrated Coronary Disease * AtheroAbzyme positive during screening process * Elevated Total Cholesterol * Willingness to take study nutritional supplement once a day for 3 months Exclusion Criteria: * Women who are pregnant, nursing or intend pregnancy during the period of treatment * Known milk, soy or whey allergy

Locations (1)

Rafic Hariri University Hospital

Beirut, Bir Hasan, Lebanon

Outcomes

Primary Outcomes

to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease

Time frame: Baseline and 3 months

Secondary Outcomes

to evaluate the potential effectiveness of Ateronon in lowering pulse rate as well systolic and diastolic blood pressure in patients with demonstrated coronary disease

Time frame: Baseline and 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.